Showing results (171-180 of 330) with videos related to
Sort By:
Pageof 33
Molecular & Cellular Proteomics : MCP|August 11, 2018
gpGrouper: A Peptide Grouping Algorithm for Gene-Centric Inference and Quantitation of Bottom-Up Proteomics DataAlexander B Saltzman, Mei Leng, Bhoomi Bhatt, et al.Breast Cancer Research and Treatment|February 19, 2009
Novel tumor sampling strategies to enable microarray gene expression signatures in breast cancer: a study to determine feasibility and reproducibility in the context of clinical careChristopher L Tebbit, Jun Zhai, Brian R Untch, et al.The New England Journal of Medicine|August 20, 2004
Circulating tumor cells, disease progression, and survival in metastatic breast cancerMassimo Cristofanilli, G Thomas Budd, Matthew J Ellis, et al.Breast Cancer Research and Treatment|June 15, 2017
Development of a Ki-67-based clinical trial assay for neoadjuvant endocrine therapy response monitoring in breast cancerRodrigo Goncalves, Katherine DeSchryver, Cynthia Ma, et al.Cancer Research Communications|August 17, 2023
Kinase Inhibitor Pulldown Assay Identifies a Chemotherapy Response Signature in Triple-negative Breast Cancer Based on Purine-binding ProteinsJunkai Wang, Alexander B Saltzman, Eric J Jaehnig, et al.The Journal of Clinical Investigation|March 27, 2012
Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor modelsCynthia X Ma, Shirong Cai, Shunqiang Li, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 7, 2006
Estrogen-independent proliferation is present in estrogen-receptor HER2-positive primary breast cancer after neoadjuvant letrozoleMatthew J Ellis, Yu Tao, Oliver Young, et al.Clinical Journal of the American Society of Nephrology : CJASN|May 27, 2021
Dialysis Facility Profit Status and Early Steps in Kidney Transplantation in the Southeastern United StatesLaura J McPherson, Elizabeth R Walker, Yi-Ting Hana Lee, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 2, 2026
Pharmacodynamics of Camizestrant Treatment in Postmenopausal Women With Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Primary Breast Cancer: Results From the Randomized, Presurgical SERENA-3 StudyJohn F R Robertson, Teimuraz Gogitidze, Zaza Katashvili, et al.JAMA|August 20, 2009
Lower-dose vs high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer: a phase 2 randomized studyMatthew J Ellis, Feng Gao, Farrokh Dehdashti, et al.Pageof 33